Search Results 761-770 of 15224 for alt

1. Study To Evaluate The Efficacy And Safety Of Elafibranor In Patients With Primary Biliary Cholangitis (PBC) And Inadequate Response To Ursodeoxycholic Acid - Mayo Clinic

   'AIH-PBC overlap syndrome' is based upon fulfilment of the Paris criteria (Chazouilléres 1998)for both AIH (ALT ≥5x ULN; IgG ≥2x ULN or smooth muscle ...

2. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair - Mayo Clinic

   Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); Thyroid-stimulating hormone (TSH) within normal limits ...

3. Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas - Mayo Clinic

   Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit ...

4. A Study of Donated Alloantigen Reactive Regulatory T Cells for Reducing or Discontinuing Immune System Suppression in Liver Transplant Patients - Mayo Clinic

   ALT and either alkaline phosphatase or GGT remain within normal limits or ≤ 1.5 x baseline after darTregs infusion; For subjects with elevated liver tests ...

5. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

   Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and alkaline phosphatase ≤ 2.5 × ULN. ... *Patients receiving immunotherapy should ...

6. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

   AST, ALT, and alkaline phosphatase ≤ 2.5 x ULN, with the following exceptions: Patients with documented liver metastases: AST and/or ALT ≤ 5 x ULN; ...

7. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma - Mayo Clinic

   Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN). For patients with significant hepatic metastases, ALT and ...

8. Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma - Mayo Clinic

   ANC ≥ 1500/mcL, AST and ALT < 2 x upper limit of normal (ULN), total bilirubin ≤ 3 mg/dL, creatinine clearance ≥ 50 mL/min, platelet count ≥ 100,000/mcL ...

9. Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma - Mayo Clinic

   ... ALT < 5 times ULN for age). Shortening fraction of >= 27%; or; Ejection fraction of >= 50%. Patients must have a normal blood sugar level for age to ...

10. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

    If attributed to tumor involvement, AST and ALT <5×ULN. Subjects a history of hepatitis (Exclusion Criterion No. 11) must have ALT within the normal range.